The DOI matches its Crossref record.
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
Abstract
BACKGROUND: Complete pathologic response of breast carcinoma to neoadjuvant chemotherapy is a well defined outcome that correlates with prolonged survival. Categorization of incomplete response depends on accurate measurement of residual tumor size but is complicated by the variable histopathologic changes that occur within the tumor bed. In the current study, the authors investigated the contribution of assessing tumor cellularity in the pathologic evaluation of response to chemotherapy. METHODS: The slides from diagnostic core needle biopsy and the subsequent matched resection specimens were examined in 240 patients with breast carcinoma: 120 “treated” patients who received neoadjuvant chemotherapy and 120 “control” patients who received primary surgical management within a few weeks of diagnosis. Clinical response and residual tumor size were evaluated in 108 treated patients who completed a clinical trial with paclitaxel and then received combined 5‐fluorouracil, doxorubicin, and cyclophosphamide chemotherapy. Tumor cellularity was assessed from hematoxylin and eosin‐stained tissue sections as the percentage of tumor area that contained invasive carcinoma. RESULTS: After neoadjuvant chemotherapy, tumor cellularity decreased from a median of 40% in core needle biopsy to 10% in resection specimens (P < 0.01; Wilcoxon signed rank test). The cellularity of core needle biopsy (median, 30%) tended to underestimate the cellularity of resection specimens (median, 40%) in the control group (P < 0.01). Changes in cellularity varied within each clinical response category, particularly partial response and minor response. The greatest reduction was observed in the cellularity of residual primary tumors that measured ≤ 1 cm (pathologic T1a [pT1a] and pT1b tumors), but changes in cellularity varied in the pT1, pT2, and pT3 residual tumor categories. The shape of the distribution of tumor size, expressed as the greatest dimension in cm, was similar in the control group and the treatment group (excluding complete pathologic response); however, when residual tumor size and cellularity were combined, the distribution of pathologic response shifted left (toward complete response) with a steep decline, suggesting that many tumors had a large reduction in cellularity but little change in the tumor size. CONCLUSIONS: Cellularity of the tumor mass was reduced significantly by neoadjuvant chemotherapy, and the change varied widely in different categories of clinical response. Although residual tumors measuring ≤ 1 cm in greatest dimension had the most reduction in tumor cellularity, there was broad variability for all residual tumor groups (pT1–pT3). The frequency distribution of residual tumor size was altered markedly by the inclusion of tumor cellularity, indicating that the product of pathologic size and tumor cellularity may provide more accurate pathologic response information than tumor size alone. Cancer 2004100:1365–73. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Self-citationHuang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., & Yan, D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505212y · Cited by 716
Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
Yuan, Y., Failmezger, H., Rueda, O. M., Ali, H. R., Gräf, S., Chin, S.-F., Schwarz, R. F., Curtis, C., Dunning, M. J., Bardwell, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004330 · Cited by 426
Tumor Redox Heterogeneity‐Responsive Prodrug Nanocapsules for Cancer Chemotherapy
Wang, J., Sun, X., Mao, W., Sun, W., Tang, J., Sui, M., Shen, Y., & Gu, Z. (2013) · Advanced Materials · doi:10.1002/adma.201300929 · Cited by 395
Sharma, U., Danishad, K. K. A., Seenu, V., & Jagannathan, N. R. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1245 · Cited by 321
Metadata
- Authors
- Rajan, R., Poniecka, A., Smith, T. L., Yang, Y., Frye, D., Pusztai, L., Fiterman, D. J., Gal‐Gombos, E., Whitman, G., Rouzier, R., Green, M., Kuerer, H., Buzdar, A. U., Hortobagyi, G. N., & Symmans, W. F.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-02-25
- Volume
- 100
- Issue
- 7
- Pages
- 1365-1373
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2059994457
- Cited by
- 162
- References
- 0
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. https://app.cochat.ai/papers/10.1002/cncr.20134
- The paper
- Rajan, R., Poniecka, A., Smith, T. L., Yang, Y., Frye, D., Pusztai, L., Fiterman, D. J., Gal‐Gombos, E., Whitman, G., Rouzier, R., Green, M., Kuerer, H., Buzdar, A. U., Hortobagyi, G. N., & Symmans, W. F. (2004). Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer. https://doi.org/10.1002/cncr.20134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.